guest ::
| Home > Publications Database > Age-Specific Control and Alzheimer Disease Reference Curves and z-Scores for Glial Fibrillary Acidic Protein in Blood. > print |
| Home > Publications Database > Age-Specific Control and Alzheimer Disease Reference Curves and z-Scores for Glial Fibrillary Acidic Protein in Blood. > print |
| 001 | 282577 | ||
| 005 | 20251218105203.0 | ||
| 024 | 7 | _ | |a 10.1093/clinchem/hvaf120 |2 doi |
| 024 | 7 | _ | |a pmid:41081630 |2 pmid |
| 024 | 7 | _ | |a 0009-9147 |2 ISSN |
| 024 | 7 | _ | |a 1530-8561 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01337 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Halbgebauer, Steffen |0 P:(DE-2719)9002026 |b 0 |e First author |
| 245 | _ | _ | |a Age-Specific Control and Alzheimer Disease Reference Curves and z-Scores for Glial Fibrillary Acidic Protein in Blood. |
| 260 | _ | _ | |a Washington, DC |c 2025 |b American Association for Clinical Chemistry |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1766051252_31261 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Serum glial fibrillary acidic protein (GFAP) is a biomarker for astrocytic injury and astrogliosis. Concentrations are elevated in numerous neurological disorders, including a pronounced increase in Alzheimer disease (AD). However, GFAP levels in the serum also increase with age. Consequently, the integration of GFAP levels into clinical routine and their interpretation demands age-adjusted reference values.Serum from 1273 subjects (952 noninflammatory and nonneurodegenerative neurological controls and 321 subjects with AD) was analyzed for GFAP using the microfluidic Ella system. Age-dependent serum GFAP reference values were estimated by additive quantile regression analysis and visualized with percentiles and z-scores.AD exhibited elevated serum GFAP levels in comparison to control patients (P < 0.0001). This remained the case when the newly generated age-corrected z-scores were applied (P < 0.0001). In the control cohort, a nonlinear elevation of serum GFAP with increasing age was observed (Spearman correlation coefficient 0.62, 95% CI 0.58-0.66, P < 0.0001). In contrast, the AD cohort exhibited a more linear increase (0.16, 95% CI 0.05-0.26, P = 0.004). Age-dependent cut-offs for serum GFAP were determined for different AD age groups. The calculated areas under the curve (AUCs; 0.97) demonstrated excellent diagnostic test performance in the early-onset age group. This effect was less marked in the elderly subjects (AUC 0.72).Our novel GFAP z-scores enable the integration and interpretation of serum GFAP levels in clinical practice, moving from the group to individual level. They support both intra- and interindividual interpretation of single GFAP levels in neurological diseases with astrocytic pathology, including an accurate discrimination of AD. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Glial Fibrillary Acidic Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a GFAP protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: blood |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Glial Fibrillary Acidic Protein: blood |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Reference Values |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Age Factors |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Case-Control Studies |2 MeSH |
| 700 | 1 | _ | |a Fazeli, Badrieh |b 1 |
| 700 | 1 | _ | |a Klose, Veronika |0 P:(DE-2719)9001084 |b 2 |
| 700 | 1 | _ | |a Nagel, Gabriele |b 3 |
| 700 | 1 | _ | |a Rosenbohm, Angela |0 P:(DE-2719)9002269 |b 4 |
| 700 | 1 | _ | |a Rothenbacher, Dietrich |0 P:(DE-2719)9002270 |b 5 |
| 700 | 1 | _ | |a Bachhuber, Franziska |b 6 |
| 700 | 1 | _ | |a Jesse, Sarah |0 P:(DE-2719)9001441 |b 7 |u dzne |
| 700 | 1 | _ | |a Otto, Markus |b 8 |
| 700 | 1 | _ | |a Landwehrmeyer, Georg Bernhard |0 P:(DE-2719)9003425 |b 9 |u dzne |
| 700 | 1 | _ | |a Abdelhak, Ahmed |0 0000-0001-9731-4169 |b 10 |
| 700 | 1 | _ | |a Petzold, Axel |0 0000-0002-0344-9749 |b 11 |
| 700 | 1 | _ | |a Ludolph, Albert C |0 P:(DE-2719)2812633 |b 12 |u dzne |
| 700 | 1 | _ | |a Tumani, Hayrettin |0 P:(DE-2719)9002007 |b 13 |u dzne |
| 773 | _ | _ | |a 10.1093/clinchem/hvaf120 |g Vol. 71, no. 12, p. 1234 - 1242 |0 PERI:(DE-600)1468161-4 |n 12 |p 1234 - 1242 |t Clinical chemistry |v 71 |y 2025 |x 0009-9147 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282577/files/DZNE-2025-01337%20SUP.zip |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/282577/files/DZNE-2025-01337.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/282577/files/DZNE-2025-01337.pdf?subformat=pdfa |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9002026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)9001084 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-2719)9001441 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 9 |6 P:(DE-2719)9003425 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2812633 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 13 |6 P:(DE-2719)9002007 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN CHEM : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CLIN CHEM : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 920 | 1 | _ | |0 I:(DE-2719)5000077 |k Clinical Study Center (Ulm) |l Clinical Study Center (Ulm) |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1910005 |k AG Zhan |l Neuroepidemiology |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000077 |
| 980 | _ | _ | |a I:(DE-2719)1910005 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|